206 related articles for article (PubMed ID: 21861214)
21. A prediction tool incorporating the biomarker S-100B for patient selection for completion lymph node dissection in stage III melanoma.
Damude S; Wevers KP; Murali R; Kruijff S; Hoekstra HJ; Bastiaannet E
Eur J Surg Oncol; 2017 Sep; 43(9):1753-1759. PubMed ID: 28797756
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of multiple serum markers in advanced melanoma.
Díaz-Lagares A; Alegre E; Arroyo A; González-Cao M; Zudaire ME; Viteri S; Martín-Algarra S; González A
Tumour Biol; 2011 Dec; 32(6):1155-61. PubMed ID: 21858537
[TBL] [Abstract][Full Text] [Related]
23. Tumour assessment in advanced melanoma: value of FDG-PET/CT in patients with elevated serum S-100B.
Strobel K; Skalsky J; Kalff V; Baumann K; Seifert B; Joller-Jemelka H; Dummer R; Steinert HC
Eur J Nucl Med Mol Imaging; 2007 Sep; 34(9):1366-75. PubMed ID: 17390135
[TBL] [Abstract][Full Text] [Related]
24. Serum S100B and LDH are not useful in predicting the sentinel node status in melanoma patients.
Egberts F; Momkvist A; Egberts JH; Kaehler KC; Hauschild A
Anticancer Res; 2010 May; 30(5):1799-805. PubMed ID: 20592382
[TBL] [Abstract][Full Text] [Related]
25. Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients.
Domingo-Domènech J; Castel T; Auge JM; Garcia-Albeniz XA; Conill C; Puig S; Vilella R; Matas J; Malvehy J; Gascón P; Mellado B; Molina R
Tumour Biol; 2007; 28(5):264-72. PubMed ID: 17962723
[TBL] [Abstract][Full Text] [Related]
26. Value of serum S-100B for prediction of distant relapse and survival in stage III B/C melanoma.
Smit LH; Nieweg OE; Mooi WJ; Bonfrer JM; Haanen JB; Kroon BB; De Gast GC
Anticancer Res; 2008; 28(4C):2297-302. PubMed ID: 18751409
[TBL] [Abstract][Full Text] [Related]
27. Role of serum S100B and PET-CT in follow-up of patients with cutaneous melanoma.
Peric B; Zagar I; Novakovic S; Zgajnar J; Hocevar M
BMC Cancer; 2011 Aug; 11():328. PubMed ID: 21810220
[TBL] [Abstract][Full Text] [Related]
28. Monitoring malignant melanoma with the S-100B tumour marker.
Bonfrer JM; Korse CM
Recent Results Cancer Res; 2001; 158():149-57. PubMed ID: 11092042
[TBL] [Abstract][Full Text] [Related]
29. [Serum levels of S-100b protein after four years follow-up of patients with melanoma].
Zissimopoulos A; Karpouzis A; Karaitianos I; Baziotis N; Tselios I; Koutis C
Hell J Nucl Med; 2006; 9(3):204-7. PubMed ID: 17160167
[TBL] [Abstract][Full Text] [Related]
30. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy.
Wagner JD; Schauwecker D; Davidson D; Coleman JJ; Saxman S; Hutchins G; Love C; Hayes JT
J Clin Oncol; 1999 May; 17(5):1508-15. PubMed ID: 10334538
[TBL] [Abstract][Full Text] [Related]
31. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
[TBL] [Abstract][Full Text] [Related]
32. [S100 protein as tumoral marker in melanoma patients. Comparative study with sentinel node biopsy and whole body FDG-PET].
Ortiz B; Vázquez C; Martínez C; Giménez J; Sanmartín O; de los Dolores V; Ortega F; Maíquez J; Fliquete MV
Rev Esp Med Nucl; 2003; 22(2):87-96. PubMed ID: 12646097
[TBL] [Abstract][Full Text] [Related]
33. The current status of S-100B as a biomarker in melanoma.
Kruijff S; Hoekstra HJ
Eur J Surg Oncol; 2012 Apr; 38(4):281-5. PubMed ID: 22240030
[TBL] [Abstract][Full Text] [Related]
34. Use of serum 5-S-CD and S-100B protein levels to monitor the clinical course of malignant melanoma.
Bánfalvi T; Gilde K; Gergye M; Boldizsár M; Kremmer T; Ottó S
Eur J Cancer; 2003 Jan; 39(2):164-9. PubMed ID: 12509947
[TBL] [Abstract][Full Text] [Related]
35. Significance of serum S-100B in melanoma patients before and after sentinel node biopsy.
Smit LH; Nieweg OE; Korse CM; Bonfrer JM; Kroon BB
J Surg Oncol; 2005 May; 90(2):66-9; discussion 69-70. PubMed ID: 15844182
[TBL] [Abstract][Full Text] [Related]
36. Melanoma progression and serum L-dopa/L-tyrosine ratio: a comparison with S100B.
Stoitchkov K; Letellier S; Garnier JP; Bousquet B; Tsankov N; Morel P; Ghanem G; Le Bricon T
Melanoma Res; 2002 Jun; 12(3):255-62. PubMed ID: 12140382
[TBL] [Abstract][Full Text] [Related]
37. Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients.
Smit LH; Korse CM; Hart AA; Bonfrer JM; Haanen JB; Kerst JM; Nieweg OE; de Gast GC
Eur J Cancer; 2005 Feb; 41(3):386-92. PubMed ID: 15691637
[TBL] [Abstract][Full Text] [Related]
38. Impact of lymph node metastases on serum level of melanoma inhibitory activity in stage III melanoma patients.
Hofmann MA; Schicke B; Fritsch A; Biesold S; Gussmann F; Küchler I; Voit C; Trefzer U
J Dermatol; 2011 Sep; 38(9):880-6. PubMed ID: 21658116
[TBL] [Abstract][Full Text] [Related]
39. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
Nowecki ZI; Rutkowski P; Michej W
Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535
[TBL] [Abstract][Full Text] [Related]
40. Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma.
Schultz ES; Diepgen TL; Von Den Driesch P
Br J Dermatol; 1998 Mar; 138(3):426-30. PubMed ID: 9580794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]